Salix Central
Artrya Limited • Radiology • 03/27/2025
Device Purpose
Salix Central is a Class II web-based medical image management and processing system designed as an adjunctive tool for the qualitative and quantitative assessment of cardiac CT images, specifically for coronary plaque, stenosis, and calcium scoring. Utilizing a SaaS model hosted on AWS, the device employs machine learning-enabled outputs and interactive post-processing tools, demonstrating substantial equivalence and successful performance testing.
Summary
A determination has been made regarding the Salix Central device, confirming its substantial equivalence to legally marketed medical devices. This Class II device, identified as a medical image management and processing system, is designed for viewing, post-processing, and analyzing cardiac computed tomography (CT) images acquired in a DICOM Standard format. It provides tools for the qualitative and quantitative assessment of physician-identified coronary plaques and stenosis in coronary computed tomography angiography (CCTA), as well as for performing calcium scoring in non-contrast cardiac CT. Intended to complement standard care, Salix Central serves as an adjunctive tool for qualified medical professionals experienced in cardiac CT image examination. The Salix Central device is a web-based software application delivered via a SaaS model and hosted on AWS cloud services. It offers interactive post-processing tools for trained radiologists and cardiologists to analyze cardiac CT image data, aiding in the preparation of standard coronary reports. The device's substantial equivalence was established through a comparison to a predicate device, the cvi42 Auto Imaging Software Application, highlighting similarities in intended use, features, and performance. Comprehensive performance testing, including verification and validation, was conducted on the device's machine learning-enabled outputs for calcium scoring, centerline extraction, vessel labeling, and lumen/vessel wall segmentation, demonstrating that it exceeded all pre-defined acceptance criteria.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. What specific clinical scenarios demonstrate the most significant improvement in diagnostic accuracy or efficiency when using Salix Central as an adjunctive tool?; How does the performance of Salix Central's machine learning algorithms for calcium scoring and lumen/vessel wall segmentation compare against a gold standard or manual expert analysis in a diverse patient cohort?; What are the data privacy and security protocols implemented for patient medical images stored and processed on the AWS cloud services by Salix Central?; Are there any known limitations or contraindications for using Salix Central, particularly concerning image quality requirements or specific patient anatomies?; What training and certification are recommended for clinicians to effectively utilize and interpret the advanced post-processing and analysis features of Salix Central?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Qualifies as a cyber device under §524B (post-Dec 2023, networked)
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly